Medtronic PLC (NYSE:MDT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Medtronic PLC (NYSE:MDT) have earned an average rating of “Moderate Buy” from the twenty-six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Ten research analysts have rated the stock with a hold recommendation, fifteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $110.8421.

A number of equities analysts have issued reports on the company. UBS Group reiterated a “neutral” rating and set a $104.00 price target on shares of Medtronic in a research note on Wednesday, February 4th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. Leerink Partners lowered their price target on Medtronic from $120.00 to $119.00 and set an “outperform” rating for the company in a research report on Wednesday, February 18th. Royal Bank Of Canada increased their price target on Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Finally, The Goldman Sachs Group set a $111.00 price objective on shares of Medtronic and gave the stock a “neutral” rating in a report on Wednesday, November 19th.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic plans to spin off its Diabetes segment via an IPO of MiniMed Group, a move that could unlock value by creating a focused, standalone diabetes business and give investors clearer exposure to high-growth diabetes assets. Medtronic Reshapes Portfolio With MiniMed IPO And Stealth AXiS Approval
• Positive Sentiment: Medtronic’s MiniMed Group is pursuing a U.S. IPO (target ~ $784m), signaling management is executing a portfolio-shaping strategy and potentially accelerating value realization for MDT shareholders. Medtronic’s diabetes business MiniMed looks for $784m in US IPO
• Positive Sentiment: Commercial rollout: Medtronic launched the MiniMed Go Smart MDI system with the Simplera sensor in EMEA — a product that integrates insulin-pen data and continuous sensor data into a single app, expanding commercial reach in diabetes care. This supports recurring-revenue potential in a growth segment. Medtronic begins EMEA commercial launch of MiniMed Go Smart MDI system with Simplera sensor
• Positive Sentiment: Product/clinical beat: Medtronic reported positive findings for its Altaviva tibial neuromodulation therapy for urinary incontinence — a clinical win that can support future commercial adoption in a meaningful urology market. Medtronic reports positive findings for Altaviva tibial neuromod for urinary incontinence
• Neutral Sentiment: Macro/relative performance: Analysts note MDT has underperformed the S&P 500 over the past year, though Wall Street remains moderately constructive — a reminder that valuation and index-relative dynamics could cap upside even as company-specific news is positive. Is Medtronic Stock Underperforming the S&P 500?
• Negative Sentiment: Insider sale: EVP & President Harry “Skip” Kiil sold 52,524 shares (transaction disclosed Feb. 19) for roughly $5.13M at an average price ~ $97.71, reducing his stake by ~61.6%. Large insider dispositions can weigh on sentiment even if they are routine or for diversification/liquidity reasons. Top Medtronic Executive Unloads a Major Chunk of Stock in High-Value Insider Deal

Medtronic Stock Performance

Shares of MDT stock opened at $96.97 on Friday. The company has a current ratio of 2.54, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The firm has a fifty day simple moving average of $98.95 and a two-hundred day simple moving average of $96.83. Medtronic has a 12 month low of $79.55 and a 12 month high of $106.33. The firm has a market capitalization of $124.50 billion, a PE ratio of 27.01, a price-to-earnings-growth ratio of 2.43 and a beta of 0.71.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business’s revenue was up 5.8% on a year-over-year basis. During the same period last year, the company earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts forecast that Medtronic will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.9%. Medtronic’s payout ratio is 79.11%.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.26% of the company’s stock.

Hedge Funds Weigh In On Medtronic

Several institutional investors have recently modified their holdings of MDT. TD Capital Management LLC lifted its holdings in Medtronic by 264.5% during the fourth quarter. TD Capital Management LLC now owns 565 shares of the medical technology company’s stock worth $54,000 after acquiring an additional 410 shares during the period. Sit Investment Associates Inc. raised its stake in shares of Medtronic by 12.7% during the 4th quarter. Sit Investment Associates Inc. now owns 90,100 shares of the medical technology company’s stock worth $8,655,000 after purchasing an additional 10,183 shares during the period. MidFirst Bank purchased a new position in shares of Medtronic in the 4th quarter worth about $2,169,000. SG Trading Solutions LLC bought a new position in Medtronic during the fourth quarter valued at about $588,000. Finally, Monetary Solutions Ltd purchased a new stake in Medtronic during the fourth quarter worth about $27,000. 82.06% of the stock is owned by institutional investors.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).